tetano
Editor, Senior Moderator
Curr Rheumatol Rev
. 2022 Apr 12.
doi: 10.2174/1573397118666220412114514. Online ahead of print.
COVID-19 Mortality in Patients with Rheumatic Diseases: A Real Concern
Nasra K Al-Adhoubi[SUP] 1 [/SUP], Maha Ali[SUP] 2 [/SUP], Humaid Al Wahshi[SUP] 1 [/SUP], Issa Al Salmi[SUP] 3 [/SUP], Farida Al-Balushi[SUP] 1 [/SUP], Talal Al Lawati[SUP] 4 [/SUP], Abeer Mohammed[SUP] 5 [/SUP], Ahmed Al Muqbali[SUP] 6 [/SUP], Hilal Al Kalbani[SUP] 7 [/SUP], Safiya Al-Abrawi[SUP] 8 [/SUP], Faryal Khamis[SUP] 9 [/SUP]
Affiliations
Abstract
Background: Coronavirus disease 2019 (COVID 19) is a worldwide pandemic that has devastated the world in a way that has not been witnessed since the Spanish Flu in 1918. In this study, we aim to investigate the outcomes of patients with rheumatic diseases infected with COVID19 in Oman.
Methods: A multi-center retrospective cohort study included patients with underlying rheumatological conditions and COVID-19 infection. Data was collected through the electronic record system and by interviewing the patients with a standard questionnaire.
Results: 113 patients with different rheumatic diseases were included with the following rheumatological diagnoses: rheumatoid Arthritis (40.7%), systemic lupus erythematosus (23.1%), psoriatic arthritis (8%), Behcet's disease (7%), ankylosing spondylitis (6.2%), other vasculitides including Kawasaki disease (4.4%) and 10.6% other diagnoses. The mean (SD) age of patients was 43 (14) years, and 82.3% were female. The diagnosis of COVID-19 was confirmed by PCR test in (84.1%) of the patients. The most common symptoms at the time of presentation were fever in 86%, cough (81%), headache (65%), and myalgia (60%). Hospitalization due to COVID-19 infection was reported in 24.1% of the patients, and 52.2 % of these patients had received some form of treatment. In this cohort, the intake of immunosuppressive and immunomodulating medications was reported in 91.1% of the patients. During the COVID-19 infection, 68% of the patients continued taking their medications. Comorbidities were present in 39.8% of the patients. Pregnancy was reported in 2% of the patients. The 30 days mortality rate was found to be 3.5%. Diabetes, obesity, and interstitial lung diseases (ILD) were the strongest risk factor for mortality (p-value 0.000, 0.000, and 0.001), respectively. Rituximab was given in 3.8 % of the patients, and it was significantly associated with increased mortality among our patients (P-value <0.001).
Conclusion: COVID-19 infection in patients with rheumatic diseases have an increased mortality rate in comparison to the general population, with diabetes, morbid obesity, chronic kidney diseases, interstitial lung disease, cardiovascular disease, obstructive lung disease, and liver diseases as comorbidities being the most risk factors associated with death. Greater care should be provided to this population, including the prompt need for vaccination.
Keywords: COVID-19; Rheumatic diseases; SARS-coV-2; autoimmune diseases; comorbidities.; immunosuppressive therapy; mortality; viral infection.
. 2022 Apr 12.
doi: 10.2174/1573397118666220412114514. Online ahead of print.
COVID-19 Mortality in Patients with Rheumatic Diseases: A Real Concern
Nasra K Al-Adhoubi[SUP] 1 [/SUP], Maha Ali[SUP] 2 [/SUP], Humaid Al Wahshi[SUP] 1 [/SUP], Issa Al Salmi[SUP] 3 [/SUP], Farida Al-Balushi[SUP] 1 [/SUP], Talal Al Lawati[SUP] 4 [/SUP], Abeer Mohammed[SUP] 5 [/SUP], Ahmed Al Muqbali[SUP] 6 [/SUP], Hilal Al Kalbani[SUP] 7 [/SUP], Safiya Al-Abrawi[SUP] 8 [/SUP], Faryal Khamis[SUP] 9 [/SUP]
Affiliations
- PMID: 35418287
- DOI: 10.2174/1573397118666220412114514
Abstract
Background: Coronavirus disease 2019 (COVID 19) is a worldwide pandemic that has devastated the world in a way that has not been witnessed since the Spanish Flu in 1918. In this study, we aim to investigate the outcomes of patients with rheumatic diseases infected with COVID19 in Oman.
Methods: A multi-center retrospective cohort study included patients with underlying rheumatological conditions and COVID-19 infection. Data was collected through the electronic record system and by interviewing the patients with a standard questionnaire.
Results: 113 patients with different rheumatic diseases were included with the following rheumatological diagnoses: rheumatoid Arthritis (40.7%), systemic lupus erythematosus (23.1%), psoriatic arthritis (8%), Behcet's disease (7%), ankylosing spondylitis (6.2%), other vasculitides including Kawasaki disease (4.4%) and 10.6% other diagnoses. The mean (SD) age of patients was 43 (14) years, and 82.3% were female. The diagnosis of COVID-19 was confirmed by PCR test in (84.1%) of the patients. The most common symptoms at the time of presentation were fever in 86%, cough (81%), headache (65%), and myalgia (60%). Hospitalization due to COVID-19 infection was reported in 24.1% of the patients, and 52.2 % of these patients had received some form of treatment. In this cohort, the intake of immunosuppressive and immunomodulating medications was reported in 91.1% of the patients. During the COVID-19 infection, 68% of the patients continued taking their medications. Comorbidities were present in 39.8% of the patients. Pregnancy was reported in 2% of the patients. The 30 days mortality rate was found to be 3.5%. Diabetes, obesity, and interstitial lung diseases (ILD) were the strongest risk factor for mortality (p-value 0.000, 0.000, and 0.001), respectively. Rituximab was given in 3.8 % of the patients, and it was significantly associated with increased mortality among our patients (P-value <0.001).
Conclusion: COVID-19 infection in patients with rheumatic diseases have an increased mortality rate in comparison to the general population, with diabetes, morbid obesity, chronic kidney diseases, interstitial lung disease, cardiovascular disease, obstructive lung disease, and liver diseases as comorbidities being the most risk factors associated with death. Greater care should be provided to this population, including the prompt need for vaccination.
Keywords: COVID-19; Rheumatic diseases; SARS-coV-2; autoimmune diseases; comorbidities.; immunosuppressive therapy; mortality; viral infection.